Veru yesterday heralded a win in a small trial of its oral microtubule inhibitor VERU-111 in hospitalised Covid-19 patients, and consequently enjoyed a 28% share price bump. But a close read of the data reveals that the findings are not quite as rosy as the company claims.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,